Valneva SE (VALN) stock
VALNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$5.66−0.10 (-1.74%)
Close on Nov 13, 2026Market cap $491.12MP/E –Yield –
Valneva operating margin
Operating margin is operating income as a percentage of revenue.
Valneva's operating margin for the twelve months ending Jun 30, 2026 was -80.5%. For fiscal 2025 it was -47.0%, against 7.9% the year before. The highest annual figure on record is 7.9% in fiscal 2024.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -47.0% | −54.8 |
| FY2024 | Dec 31, 2024 | 7.9% | +61.3 |
| FY2023 | Dec 31, 2023 | -53.4% | −22.0 |
| FY2022 | Dec 31, 2022 | -31.4% | −13.8 |
| FY2021 | Dec 31, 2021 | -17.6% | +32.3 |
| FY2020 | Dec 31, 2020 | -50.0% | −49.3 |
| FY2019 | Dec 31, 2019 | -0.6% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -75.0% | −52.5 |
| Q1 FY2026 | Mar 31, 2026 | -76.7% | −64.6 |
| Q4 FY2025 | Dec 31, 2025 | -59.0% | −19.5 |
| Q3 FY2025 | Sep 30, 2025 | -126.2% | −99.0 |
| Q2 FY2025 | Jun 30, 2025 | -22.5% | +34.1 |
| Q1 FY2025 | Mar 31, 2025 | -12.1% | −220.4 |
| Q4 FY2024 | Dec 31, 2024 | -39.4% | +20.0 |
| Q3 FY2024 | Sep 30, 2024 | -27.2% | +31.2 |
| Q2 FY2024 | Jun 30, 2024 | -56.6% | −10.9 |
| Q1 FY2024 | Mar 31, 2024 | 208.2% | +257.7 |
| Q4 FY2023 | Dec 31, 2023 | -59.4% | −8.9 |
| Q3 FY2023 | Sep 30, 2023 | -58.3% | −117.9 |
| Q2 FY2023 | Jun 30, 2023 | -45.7% | +139.2 |
| Q1 FY2023 | Mar 31, 2023 | -49.5% | +34.9 |
| Q4 FY2022 | Dec 31, 2022 | -50.6% | −113.9 |
| Q3 FY2022 | Sep 30, 2022 | 59.6% | +737.3 |
| Q2 FY2022 | Jun 30, 2022 | -184.9% | +41.7 |
| Q1 FY2022 | Mar 31, 2022 | -84.3% | +49.8 |
| Q4 FY2021 | Dec 31, 2021 | 63.3% | – |
| Q3 FY2021 | Sep 30, 2021 | -677.7% | – |
| Q2 FY2021 | Jun 30, 2021 | -226.6% | – |
| Q1 FY2021 | Mar 31, 2021 | -134.1% | – |
See a number that looks wrong?